[Click eStock] "Neopharm Expected to Surpass 100 Billion KRW in Sales This Year"

Hana Securities analyzed on the 5th that Neopharm is expected to surpass 100 billion KRW in sales this year and continue growth-oriented management.

Park Eun-jung, a researcher at Hana Securities, stated in a report on the same day, “Neopharm recorded its highest quarterly sales with 27.3 billion KRW in revenue and 6.9 billion KRW in operating profit in Q4, meeting consensus estimates,” adding, “This was thanks to each brand such as Zeroid, Atopalm, Real Barrier, and Dermabee expanding their sales channels evenly across online/offline and exports.”

Researcher Park Eun-jung forecasted, “Neopharm’s performance this year will see consolidated sales of 120 billion KRW and operating profit of 31.7 billion KRW, growing 21% and 25% respectively compared to the previous year,” and expected, “They will focus on overseas growth targeting major markets such as the United States and Japan.”

He added, “Additionally, in Q1, Atopalm is scheduled to obtain China’s hygiene approval, and Zeroid will attend Chinese hospital and clinic academic conferences,” and predicted, “The export ratio will be raised to 40% of sales within the next three years.”

He also noted, “Not only overseas but also domestic responses have been active, and investments for brand renewal and awareness enhancement have been made,” expressing expectations that “In the case of Zeroid, a new SKU in the MD line is scheduled to launch, which will drive additional growth as it is the first new product release in a long time.”

He continued, “Overall, the company is transforming into growth-oriented management, and the current market capitalization is only 210 billion KRW, with a price-to-earnings ratio (PER) of about 7 times.”

This content was produced with the assistance of AI translation services.